Visa Joins Mastercard in Cutting Revenue Outlook on Virus Impact
(Bloomberg) -- Visa Inc. became the latest payments firm to face a hit from the spread of coronavirus.
The company warned that cardholders' spending overseas has slowed sharply, especially for travel related purchases, and that this quarter's revenue growth will be about 2.5 to 3.5 percentage points lower than the outlook it shared on Jan. 30. Visa said it won't give a forecast for future quarters until its earnings call in April.
“Cross-border growth rates have deteriorated week by week since the coronavirus outbreak in China, and trends through Feb. 28, 2020, do not yet fully reflect the impact of the coronavirus spreading outside of Asia,” San Francisco-based Visa said in a filing Monday. “As such, we anticipate that this deteriorating trend has not bottomed out yet.”
Visa joins Mastercard Inc. and PayPal Holdings Inc. in warning investors about how the spread of coronavirus might impact their business. Mastercard said last month it's knocking 2 to 3 percentage points off an earlier forecast, which translates to revenue growth of 9% to 10% on a currency-neutral basis, excluding acquisitions.
Cross-border e-commerce hasn't been significantly impacted, except for travel spending and in some Asian markets, Visa said.
Visa shares, which jumped 5.8% on Monday, gave back some of those gains after the announcement, slipping 1.2% at 5:02 p.m. in late trading.
To contact the reporter on this story: Jenny Surane in New York at jsurane4@bloomberg.net
To contact the editors responsible for this story: Michael J. Moore at mmoore55@bloomberg.net, Peter Eichenbaum
©2020 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.